Zusammenfassung
Die venöse Thrombose gehört mit einer Inzidenz von etwa 1:1.000 pro Jahr zu den häufigsten Erkrankungen. Das individuelle Thromboserisiko ist von dem genetischen Hintergrund und dem Vorliegen von exogenen Risikofaktoren abhängig. Zu den häufigsten hereditären Risikofaktoren gehören die Faktor-V-Leiden-Mutation und die Prothrombin-G20210A-Mutation. Prädisponierende Risikosituationen sind u. a. Operationen, Traumata, Immobilisation und Tumorerkrankungen. Damit ist die venöse Thromboembolie ein typisches Beispiel einer multikausalen Erkrankung.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Cohen AT, Agnelli G, Anderson FA et al. (2007) Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 98: 756–764
Goldhaber S (2004) Pulmonary embolism. Lancet 363: 1295–305
Goldhaber SZ (2002) Echocardiography in the management of pulmonary embolism. Ann Intern Med 136: 691–700.
Grifoni S, Vanni S, Magazzini S, Olivotto I, Conti A, Zanobetti M, Polidori G, Pieralli F, Peiman N, Becattini, C, Agnelli G (2006) Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med 166: 2151–6
Heit JA (2005) Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 3: 1611–7
Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O’Fallon WM, Melton LJ 3rd. (2001) The epidemiology of venous thromboembolism in the community. Thromb Haemost 86: 452–63
Killewich LA, Bedford GR, Beach KW, Strandness DE Jr. (1989) Spontaneous lysis of deep venous thrombi: rate and outcome. J Vasc Surg 9: 89–97
Kuipers S, Schreijer AJ, Cannegieter SC, Büller HR, Rosendaal FR, Middeldorp S (2007) Travel and venous thrombosis: a systematic review. J Intern Med 262: 615–34
Kyrle PA, Eichinger S (2005) Deep vein thrombosis. Lancet 365: 1163–74
Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S (2004) The risk of recurrent venous thromboembolism in men and women. N Engl J Med 350: 2558–63
Mannucci PM (2002) The measurement of multifactorial thrombophilia. Thromb Haemost 88: 1–2
Moser KM, Le Moine JR (1981) Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med 94: 439–44
Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J (2007) Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5: 692–9
Nicolaides AN, Kakkar VV, Field ES, Renney JT (1971) The origin of deep vein thrombosis: a venographic study. Br J Radiol 44: 653–63
Pieralli F, Olivotto I, Vanni S, Conti A, Camaiti A, Targioni G, Grifoni S, Berni G (2006) Usefulness of bedside testing for brain natriuretic Peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol 97: 1386–90
Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton, LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-yearpopulation-based study. Arch Intern Med 158: 585–93
Task Force on Pulmonary Embolism, European Society of Cardiology (2000) Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 21: 1301–1336
ten Wolde M, Sohne M, Quak E, Mac Gillavry, MR Buller, HR (2004) Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med 164: 1685–9
Literatur
Ambruso DR, Leonard BD, Bies RD et. al. (1982) Antithrombin III deficiency: decreased synthesis of a biochemically normal molecule. Blood 60: 78
d’Angelo A, Vigano-DÁngelo S, Esmon CT et al. (1988) Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation. J Clin Invest 81: 1445
d’Angelo S, Comp PC, Esmon CT et al. (1986) Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 77: 416
Bernard GR, Vincent JL, Laterre PF et al.; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699–709
Bertina RM (2000) Protein C deficiency and venous thrombosis — the search for the second genetic defect. Thromb Haemost 83: 360–1
Bertina RM, Koeleman BPC, Koster T et al. (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369: 64
Bertina RM, Broekmans AW, Krommenhoek-van Es C et al. (1984) The use of a functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency. Thromb Haemost 51: 1
Bock SC, Harris JF, Balazs I et. al. (1985) Assignment of the human antithrombin III structural gene of chromosome 1q23–q25. Cytogenet Cell Genet 39: 67
Boerger LM, Morris PC, Thurnau GR et al. (1987) Oral contraceptives and gender affect protein S status. Blood 69: 692
Broekmans AW, Bertina RM, Reinalda-Poot J et al. (1985) Hereditary protein S deficiency and venous thromboembolism. A study in three Dutch families. Thromb Haemost 53: 273
Branson HE, Katz J, Marble R et al. (1983) Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet 2: 1165
Brouwer JL, Veeger NJ, van der Schaaf W et al. (2005) Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol 128: 703
de Bruijn SF, Stam, J, Koopman mm et al. (1998) Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group. BMJ 316: 589
Candrina R, Goppini A, Salvi A et al. (1986) Arterial thrombosis in antithrombin III deficiency. Clin Lab Haematol 8: 267
Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR (2005) Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293: 2352–61
Clouse LH, Comp PC (1986) The regulation of hemostasis: The protein C system. N Engl. J Med 314: 1298
Comp PC, Nixon R, Cooper MR (1984) Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 74: 2082
Comp PC, Thurnau GR, Welsh J et al. (1986) Functional and immunologic protein S levels are decreased during pregnancy. Blood 68: 881
Conard J, Bauer KA, Gruber A et al. (1993) Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. Blood 82: 1159
Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR (2004) Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 117: 19–25
Dahlbäck B, Carlsson M, Svensson PJ (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90: 1004–8
Damus PS, Wallace GA (1975) Immunologic measurement of antithrombin III-heparin cofactor and alpha2 macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy. Thromb Res 6: 27
De Stefano V, Mastrangelo S, Schwarz HP, Pola P, Flore R, Bizzi B, Leone G (1993) Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency. Thromb Haemost. 70: 247–9
Demers C, Ginsberg JS, Hirsh J et al. (1992) Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med 116: 754
Demers C, Henderson P, Blajchman MA et al. (1993) An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 69: 231
Doggen CJ, Rosendaal FR, Meijers JC (2006) Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood 108: 4045–51
Dreyfus M, Magny JF, Bridey F et al. (1991) Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 325: 1565
Dykes AC, Walker ID, McMahon AD et al. (2001) A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 113: 636
Egeberg O (1965) Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 13: 516
Eichinger S, Weltermann A, Mannhalter C, Minar E, Bialonczyk C, Hirschl M, Schonauer V, Lechner K, Kyrle PA (2002) The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 162: 2357–60
Eichinger S, Minar E, Hirschl M et al. (1999) The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 81: 14
Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL (2001) Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism — pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 86: 809–16
Engesser L, Broekmans AW, Briet E et al. (1987) Hereditary protein S deficiency: Clinical manifestations: Ann Intern Med 106: 677
Esmon CT (1992) Protein S and protein C. Biochemistry, physiology, and clinical manifestation of deficiencies. Trends Cardiovasc Med 2: 214
Feinbloom D, Bauer KA (2005) Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 25: 2043–53
Fisher M, Fernandez JA, Ameriso SF, Xie D, Gruber A, Paganini-Hill A, Griffin JH (1996) Activated protein C resistance in ischemic stroke not due to factor V arginine 506 glutamine mutation. Stroke 27: 1163–6
Foster DS, Yoshitake S, Davie EW (1985) The nucleotide sequence of the gene for human protein C. Proc Natl Acad Sci USA 82: 4673
Gandrille S, Borgel D, Sala N et al. (2000) Protein S deficiency: a database of mutations-summary of the first update. Thromb Haemost 84: 918
Gandrille S, Borgel D, Eschwege-Gufflet V et al. (1995) Identification of 15 different candidate causal point mutations and 3 polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. Blood 85: 130
Gerson WT, Dickerman JD, Bovill EG et al. (1993) Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate. Pediatrics 91: 418
Girolami A (1987) The incidence of thrombotic manifestations in AT III abnormalities. Thromb Haemost 57: 123
Grandone E, Margaglione M, Colaizzo D, D’Andrea G, Cappucci G, Brancaccio V, Di Minno G (1998) Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 179: 1324–8
Griffin JH, Evatt B, Zimmermann TS, Kleiss AJ (1981) Deficiency of protein C in congenital thrombotic disease. J Clin Invest 68: 1370–3
Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B (2001) Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 110: 91–6
Hayashi T, Nishioka J, Shigekiyo T et al. (1994) Protein S Tokushima: abnormal molecule with substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood 83: 683
Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG (2002) Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 100: 3–10
Kauffmann RH, Veltkamp JJ, Van Tilburg NH, Van Es LA (1978) Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 65: 607
Koeleman BPC, Reitsma PH, Bertina RM (1997) Familial thrombophilia: A complex genetic disorder. Semin Hematol 34: 256
Koeleman BP, Reitsma PH, Allaart CF, Bertina RM (1994) Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 84: 1031–5
Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345: 152–5
Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM (1993) Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342: 1503–6
Kyrle PA, Minar E, Hirschl M et al. (2000) High plasma levels of factor VII and the risk of recurrent venous thromboembolism. N Engl J Med 343: 457–62
Lane DA, Bayston T, Olds RJ et al. (1997) Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the Internationel Society on Thrombosis and Haemostasis. Thromb Haemost 77: 197
Lane DA, Mannucci PM, Bauer KA et al. (1996) Inherited thrombophilia, Part 1. Thromb Haemost 76: 651
Lechner K, Kyrle PA. (1995) Antithrombin III concentrates — Are they clinically useful? Thromb Haemost 73: 340
Legnani C, Cini M, Cosmi B, Mattarozzi S, Lo Manto G, Palareti G (2004) Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis. Thromb Haemost 91: 712–8
Lensen R, Bertina RM, Vancenbroucke JP, Rosendaal FR (2001) High factor VIII levels contribute to the thrombotic risk in families with factor V Leiden. Br J Haematol 114: 380
Lind B, Johnson A, Thorsen S (1997) Naturally occurring Arg-1 to His mutation in human protein C leads to aberrant propeptide processing and secretion of dysfunctional protein C. Blood 89: 2807
Maclean PS, Tait RC (2007) Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs 67: 1429–40
Mahasandana C, Suvatta V, Marlar RA et al. (1990) Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet 335: 61
Mammen EF (1998) Antithrombin: Its physiological importance and role in DIC. Semin Thromb Hemost 24: 19
Martinelli I, Sacchi E, Landi G et al. (1998) High risk of cerebral vein thrombosis in carriers of a prothrombin gene mutation and in users of oral contraceptives. N Engl J Med 338: 1793
Martinelli I, Mannucci PM, de Stefano VD et al. (1998) Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 families. Blood 92: 2353
Mateo J, Oliver A, Borrell M et al. (1997) Laboratory evaluation and clinical characteristics of 2132 consecutive unselected patients with venous thromboembolism — results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 77: 444
McColl MD, Ramsay JE, Tait RC, Walker ID, Mc Call F, Conkie JA, Carty MJ, Greer IA (1997) Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 78: 1183–8
McGhee WG, Klotz TA, Epstein DJ, Rapaport SI (1984) Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med 101: 59
Michiels JJ, Hamulyak K (1998) Laboratory diagnosis of hereditary thrombophilia. Semin Thromb Hemost 24: 309
Miletich JP, Sherman L, Broze GJ Jr (1987) Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 317: 991
Mitchell L, Andrew M, Hanna K et al. (2003) Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving I-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 90: 235
Mosnier LO, Zlokovic BV, Griffin JH (2007) The cytoprotetive protein C pathway. Blood 109: 3161
Mustafa S, Mannhalter C, Rintelen C et al. (1998) Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden. Blood Coagul Fibrinolysis 9: 85
Nicolaes GA, Dahlbäck B (2002) Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol 22: 530–8
Pabinger I, Schneider B (1996) Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose-und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 16: 742–8
Peters C, Casella JF, Marlar RA et al. (1988) Homozygous protein C deficiency: Observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy. Pediatrics 81: 272
Ploos van Amstel HK, van der Zanden AL, Bakker E et al. (1987) Two genes homologous with protein S cDNA are located on chromosome 3. Thromb Haemost 58: 982
Plutzky J, Hoskins JA, Long GL, Crabtree GR (1986) Evolution and organization of the human protein C gene. Proc Natl Acad Sci USA 83: 546
Poort SR, Rosendaal FR, Reitsma PH et al. (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated prothrombin levels and an increase in venous thrombosis. Blood 88: 3698
Rees DC, Cox M, Clegg JB (1995) World distribution of factor V Leiden. Lancet 346: 1133–4
Reitsma PH (1997) Protein C deficiency: From gene defects to disease. Thromb Haemost 78: 344
Rezende SM, Simmonds RE, Lane DA (2004) Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood 103: 1192
Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ (1997) Interrelation of hyperhomocyst (e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 95: 1777–82
Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP (1995) Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332: 912–7
Rintala E, Seppala OP, Kotilainen P et al. (1998) Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med 26: 965
Rosendaal FR Doggen CJ, Zivelin A et al. (1998) Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79: 706
Ryan DH, Crowther MA, Ginsberg JS, Francis CW (1998) Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med 128: 270–6
Sallah S, Abdallah JM, Gagnon GA (1998) Recurrent warfarin-induced skin necrosis in kindreds with protein S deficiency. Haemostasis 28: 25
Schmidel DK, Tataro AV, Phelps LG et al. (1990) Organization of the human protein S genes. Biochemistry 29: 7845
Schwarz HP, Fischer M, Hopmeier P et al. (1984) Plasma protein S deficiency in familial thrombotic disease. Blood 64: 1297
Seligsohn U, Berger A, Abend M et al. (1984) Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 310: 559
Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A (1997) The risk of recurrent venous thromboembolism in patients with an Arg506-Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 336: 399–403
Simioni P, Prandoni P, Lensing AW et al. (2000) Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 96: 3329
Simmonds RE, Ireland H, Lane DA et al. (1998) Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect. Ann Intern Med 128: 8
Simmonds RE, Ireland H, Kunz G et al. (1996) Identification of 19 protein S gene mutations in patients with phenotypic protein S deficiency and thrombosis. Blood 88: 4195
Smiles AM, Jenny NS, Tang Z, Arnold A, Cushman M, Tracy RP (2002) No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the Cardiovascular Health Study. Thromb Haemost 87: 614–21
Steen M, Norstrom EA, Tholander AL et al. (2004) Functional characterization of factor V-I1e359Thr: A novel mutation associated with thrombosis. Blood 103: 3381
Svensson PJ Dahlback B (1994) Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330: 517–22
Tait RC, Walker ID, Reitsma PH et al. (1995) Prevalence of protein C deficiency in the healthy population. Thromb Haemost 73–87
Tait RC, Walker ID, Perry DJ et.al (1994) Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 87: 106
Thaler E, Lechner K (1981) Antithrombin III deficiency and thromboembolism. In: Prentice CRM (ed) Clinics in Haematology, vol 10. London: Saunders, p 369
Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P (1999) The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. Arterioscler Thromb Vasc Biol 19: 1776–83
Tripodi A, Mannucci PM (2001) Laboratory Investigation of thrombophilia. Clin Chem 47: 1597–606
Van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J, Lane DA (1996) Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 75: 417–21
Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR (1994) Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344: 1453–7
Van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PT, Hofman A, Grobbee DE, Kluft C (1996) Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 125: 265–9
Van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR (2000) High levels of factor IX increase the risk of venous thrombosis. Blood 15 95: 3678–82
Warren BL, Eid A, Singer P et al. (2001) Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286: 1869–78
Weenink GH, Kahle LH, Lamping RJ et al. (1984) Antithrombin III in oral contraceptive users and during normotensive pregnancy. Acta Obstet Gynecol Scand 63: 57
Weltermann A, Eichinger S, Bialonczyk C, Minar E, Hirschl M, Quehenberger P, Schonauer V, Kyrle PA (2003) The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost 1: 28–32
Williamson D, Brown K, Luddington R et al. (1998) Factor V Cambridge. A new mutation (Arg306 to Thr) associated with resistance to activated protein C. Blood 91: 1140
Zauber NP, Stark MW (1986) Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Intern Med 104: 659
Zakai NA, Katz R, Jenny NS, Psaty BM, Reiner AP, Schwartz SM, Cushman M (2007) Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. J Thromb Haemost 5: 1128–35
Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlback B (1995) Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 85: 3518–23
Zöller B, Garcia de Frutos P, Dahlbäck B (1995) Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 85: 3524
Literatur
British Society for Haematology (2000) Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 109: 704–15
Conley C, Hartmann RC (1952) A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 31: 621–2
Crowther MA, Ginsberg JS, Julian J et al. (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349: 1133–8. Erratum in: N Engl J Med 2003; 349: 2577. N Engl J Med 2004; 351: 200
Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR (2004) Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 117: 19–25
Finazzi G, Marchioli R, Brancaccio V et al. (2005) A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) J Thromb Haemost 3: 848–53
Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101: 1827–32
Harris EN, Asherson RA, Gharavi AE, Morgan SH, Derue G, Hughes GR (1985) Thrombocytopenia in SLE and related autoimmune disorders: association with anti-cardiolipin antibody. Br J Haematol 59: 227–230
Hughes GR (1993) The antiphospholipid syndrome: ten years on. Lancet 342: 341–4
Hulstein JJJ, Lenting PJ, de Laat B, Derksen RHWM, Fijnheer R, de Groot PG (2007) Beta2-glycoprotein I inhibits von Willebrand Factor-dependent platelet adhesion and aggregation. Blood 110: 1483–91
Kearon C, Gent M, Hirsh J et al. (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340: 901–7. Erratum in: N Engl J Med 1999, 341: 298
Levine JS, Branch DW, Rauch J (2002) The Antiphospholipid Syndrome. N Engl J Med 346: 752–63
Lim W, Crowther MA, Eikelboom JW (2006) Management of Antiphospholipid Antibody Syndrome. A systematic review. JAMA 295: 1050–7
Miyakis S, Lockshin MD, Atsumi T et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 4: 295–306
Pabinger I, Vormittag R (2005) Thrombophilia and pregnancy outcomes. J Thromb Haemost 3: 1603–10
Runchy SS, Folsom AR, Tsai MY, Cushman M, McGovern PD (2002) Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 119: 1005–10
Wilson WA, Gharavi AE, Koike T et al. (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 42: 1309–11
Literatur
Amiral J, Vissac AM (2007) Role of Heparin-dependent antigens in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A (eds) Heparin-induced thrombocytopenia, 4rd ed. New York: Marcel Dekker, p 131–147
Campbell KR, Mahaffey KW, Lewis BE, Weitz JI, Berkowitz SD, Ohman EM, Califf RM (2000) Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol 12(Suppl F): 14F–9
Chong BH, Magnani HN (2007) Danaparoid for the treatment of heparininduced thrombocytopenia. In: Warkentin TE, Greinacher A (eds) Heparin-induced thrombocytopenia, 4rd ed. New York: Marcel Dekker, p 319–343
Farner B, Eichler P, Kroll H, Greinacher A (2001) A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 85: 950–7
Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, Ramon R, Baggio G, Fabris F, Girolami A (2003) The incidence of heparininduced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 101: 2955–9
Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, Eichler P, Warkentin TE (2007) Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA classes. Thromb Haemost 5(8): 1666–73
Greinacher A, Eichler P, Lietz T, Warkentin TE (2005a) Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood 106: 2921–2
Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P (2005b) Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 94: 132–5
Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M (2000) Heparininduced thrombocytopenia with thromboembolic complications: meta-analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96: 846–51
Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C (1995) Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 74: 886–92
Harder S, Graff J, Klinkhardt U, von Hentig N, Walenga JM, Watanabe H, Osakabe M, Breddin HK (2004) Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time. Thromb Haemost 91: 1137–45
Koster A, Chew D, Grundel M, Bauer M, Kuppe H, Spiess BD (2003) Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg 96: 383–6
Koster A, Dyke CM, Aldea G, Smedira NG, McCarthy HL 2nd, Aronson S, Hetzer R, Avery E, Spiess B, Lincoff AM (2007) Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 83: 572–7
Lee DH, Warkentin TE (2007) Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A (eds) Heparin-induced thrombocytopenia, 4rd ed. New York: Marcel Dekker, p 67–116
Lewis BE, Hursting MJ (2007) Argatroban therapie in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A (eds) Heparininduced thrombocytopenia, 4rd ed. New York: Marcel Dekker, p 479–408
Lindhoff-Last E, Piechottka GP, Rabe F, Bauersachs R (2000) Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res 100: 55–60
Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A (2006) Evaluation of Pretest Clinical Score (4 T’s) for the Diagnosis of Heparin-Induced Thrombocytopenia in Two Clinical Settings. J Thromb Haemost 4: 759–65
Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A (2002) Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 122: 37–42
Lubenow N, Eichler P, Lietz T, Greinacher A; HIT Investigators Group (2005) Lepirudin in patients with heparin-induced thrombocytopenia — results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 3: 2428–36
Martel N, Lee J, Wells PS (2005) Risk of heparin induced thrombocytopenia with unfractionated and low molecular weight heparin thromboprophylaxis: a meta-analysis. Blood 106: 2710–5
Pötzsch B, Klovekorn WP, Madlener K (2000) Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 343: 515
Rauova L, Poncz M, McKenzie SE, Reilly MP, Arepally G, Weisel JW, Nagaswami C, Cines DB, Sachais BS (2005) Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 105: 131–8
Savi P, Chong BH, Greinacher A et al. (2005) Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 105: 139–44
Selleng K, Warkentin TE, Greinacher A (2007) Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 35(4): 1165–7.6
Selleng S, Lubenow N, Wollert H-G, Müllejans B, Greinacher A (2000) Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin. Ann Thorac Surg 71: 1041–2
Warkentin TE, Maurer BT, Aster RH (2007) Heparin-induced thrombocytopenia associated with fondaparinux
Warkentin TE, Kelton JG (2001a) Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135: 502–6
Warkentin TE, Kelton JG (2001b) Temporal aspects of heparin-induced thrombocytopenia. N Enlg J Med 344: 1286–92
Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332: 1330–5
N Engl J Med 356: 2653–5; discussion 2653–5
Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF (1999) Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 106: 629–35
Literatur
Bates SM, Greer IA, Pabinger I et al.; American College of Chest Physicians (2008) Venous thromboembolism, Thrombophilia, Antithrombotic Treatment and Pregnancy: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (Eighth Edition). Chest 133(Suppl. 6): 844S–886S
Brill-Edwards P, Ginsberg JS, Gent M (2000) Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 343: 1439–44
British Society for Haematology (2000): Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 109: 704–71
Carbillon L, Letamendia-Richard E, Lachassinne E, Fai O, Aurousseau MH (2005) Neonatal thrombosis associated with maternal antiphospholipid syndrome. J Pediatr Hematol Oncol 27: 56
Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, VanDosten P, Landon M, Miodovik M, Meis P, Thurnau G (1998) Low dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med 338: 701–5
Cervera R, Asherson RA, Acevedo ML (2004) Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 63: 1312–1317
CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) (1994) a randomized trial of low-dose aspirin for the prevention of preeclampsia among 9364 pregnant women. Lancet 343: 619–29
Galli M, Barbui T (2003) Antiphospholipid antibodies and pregnancy. Best Pract Res Clin Haematol 16: 211–25
Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, Sandmann W, Zotz RB (2000) Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 342: 374–80
Greer IA, Nelson-Piercy C (2005) Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106: 401–7
Gris JC, Mercier E, Quere I (2004) Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 103: 3695–9
Kosmas IP, Tatsioni A, Ioannidis JP (2004) Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 22: 1655–62
Kosmas IP, Tatsioni A, Ioannidis JP (2003) Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 21: 1221–8
Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB (1999) Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 340: 9–13
Kuttheh WH (1996) Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 174: 1584–158
Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN (2005) Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 93: 63–9
Lindqvist PG, Svensson PJ, Marsaal K, Grennert L, Luterkort M, Dahlback B (1999) Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 81: 532–7
McColl MD, Ramsay JE, Tait RC, Walker ID, McCall F, Conkie JA, Carty MJ, Greer IA (1997) Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 78: 1183–8
Murphy RP, Donoghue C, Nallen RJ, D’Mello M, Regan C, Whitehead AS, Fitzgerald DJ (2000) Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 20: 266–70
Pabinger I, Grafenhofer H, Kaider A, Kyrle PA, Quehenberger P, Mannhalter C, Lechner K (2005) Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. Thromb Haemost 3: 949–54
Pabinger I, Grafenhofer H, Kyrle PA, Quehenberger P, Mannhalter C, Lechner K, Kaider A (2002) Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 100: 1060–2
Pabinger I, Nemes L, Rintelen C (2000) Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. Hematol J 1: 37–41
Pabinger I, Schneider B (1996) Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose-und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 16: 742–8
Rai R, Shlebak A, Cohen H, Backos M, Holmes Z, Marriott K, Regan L (2001) Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 16: 961–5
Rai R, Cohen H, Dave M, Regan L (1997) Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipids antibodies (or antiphospholipid antibodies). Br Med J 314: 253–257
Rey E, Kahn SR, David M, Shrier I (2003) Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 361: 901–8
Salomon O, Steinberg DM, Tamarin I, Zivelin A, Seligsohn U (2005) Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis 16: 37–41
Toglia MR, Weg JG (1996) Venous thromboembolism during pregnancy. N Engl J Med 335: 108–14
Wilson QA et al. (1999) International Consensus Statement on Preliminary Classification Criteria for Definite Antiphospholipid Syndrome. Arthritis & Rheumatism 42: 1309–1311
Wisloff F, Crowther M (2004) Evidence-based treatment of the antiphospholipid syndrome. I. Pregnancy failure. Thromb Res 114: 75–81
Younis JS, Brenner B, Ohel G, Tal J, Lanir N, Ben-Ami M (2000) Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol 43: 31–5
Literatur
Bloemenkamp K, Rosendaal F, Büller H et al.(1999) Risk of venous thrombosis with use of current low-dose oral contraception is not explained by diagnostic suspicion and referral bias. Arch Intern Med 159: 65–70
Bloemenkamp K, Rosendaal F, Helmerhorst F et al. (1995) Enhancement by FV-leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet 346: 1593–1596
Canonico M, Oger E, Plu-Bureau G et al. (2007) Hormone therapy and venous thromboembolism among postmenopausal woman: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115: 840–845
Cole J, Norman H, Doherty M et al. (2007) Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 109: 339–346
Dentali F, Crowther M, Ageno W (2006) Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a metaanalysis. Blood 107: 2766–2773
Farmer RDT, Lawrenson RA, Thompson CR et al. (1997) Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 349: 83–88
Gerstman B, Piper T, Tomita D et al. (1991) Oral contraceptive estrogen dose and the risk of venous thromboembolic disease. Am J Epidemiol 133: 32–37
Gomes MPV, Deitcher SR (2004) Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. Arch Intern Med 164: 1965–1976
Grady O, Wenger N, Herrington D et al. (2000) Postmenopausal hormone therapy increases risk for venous thromboembolic disease the heart and estrogen/progestin replacement study. Arch Intern Med, 132: 689–696
Grodstein F, Stampler M, Goldhaber S et al. (1996) Prosepctive study of exogenous hormones and risk of pulmonary embolism in women. Lancet 348: 983–987
Heinemann LA, Assmann A, DoMinh T et al. (1999) Oral progestogenonly contraceptives and cardiovascular risk: results from the translational study on oral contraceptives and the health of young woman. Eur J Contracept Reprod Health Care 4: 67–73
Hulley S, Furberg C, Barrett-Connor E et al. (2002) Non-cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 288: 58–66
Jick H, Jick S, Gurewich V et al. (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in woman using oral contraceptives with differing progestagens components. Lancet 346: 1589–1593
Jick S, Kaye J, Russmann S et al. (2006) Risk of nonfatal venous thromboembolism in woman using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 73: 223–228
Jordan W (1961) Pulmonary embolism. Lancet 1: 1146–1147
Kemmeren J, Algra A, Grobbee D (2001) Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Br Med J 323: 131–134
Lewis M, Heineman L, MacRae K et al. (1996) The increased risk of venous thromboembolism and the use of third-generation progestagens: role of bias in observational research. Contraception 54: 5–13
Lidegard O, Edström B, Kreiner S (2002) Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 65: 187–196
Lidegard O, Edström B, Kreiner S (1998) Oral contraceptives and venous thromboembolism: a case-control study. Contraception 57: 291–301
Lowe G, Woodward M, Vessey M et al. (2000) Thrombotic variables and risk of idiopathic venous thromboembolism in woman aged 45-65 years: relationships to hormone replacement therapy. Thromb Haemost 83: 530–535
Martinelli I (2001) Risk factors in venous thromboembolism. Thromb Haemost 86: 395–403
Martinelli I, Taioli E, Bucciarelli P et al. (1999) Interaction between the G20210A mutation of prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 19: 700–770
Poulter NR, Chang CL, Farley TMM et al. (1999) Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications [letter]. Lancet 354: 1610
Poulter NR, Chang CL, Farley TMM et al. (1995) Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case-control study. Lancet 346: 1575–1582
Primignani M, Martinelli I, Bucciarelli P et al. (2005) Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 41: 603–608
Rosendaal FR, Vessey M, Rumley A et al. (2002) Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 116: 851–854
Scarabin P, Oger E, Plu-Bureau G, on behalf of the EStrogen and THromboEmbolism risk (ESTHER) study group (2003) Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362: 428–432
Spitzer WO, Lewis MA, Heinemann LAJ et al. (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 312: 83–88
UK Committee on Safety of Medicines and Medicines and Healthcare Products Regulatory Agency (2003) HRT: update on the risk of breast cancer and long-term safety. Curr Probl Pharmacovigilance 29:1–3
Varas-Lrenzo C, Garcia-Rodriguez LA, Cattaruzzi C et al. (1998) Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern france. Am J Epidemiol 147: 387–390
Vasilakis C, Jick H, Melero-Montes mm (1999) Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 354: 1610–1611
Vessey M, Mant D, Smith A et al. (1986) Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J 292: 526
WHO (1995) Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World health organization collaborative study of cardiovascular disease and steroid hormone contraception. Lancet 346: 1582–1588
World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception (1998) Cardiovascular disease and use of oral and injectable progesteron-only contraceptives and combined injectable contraceptives: results of an international, multicenter, case-control study. Contraception 57: 315–324
Writing group for the women’s health initiative investigators (WHI) (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled tiral. JAMA 288: 321–333
Wu O, Robertson L, Twaddle S et al. (2005) Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 131: 80–90
Literatur
Akl EA, Karmath G, Yosuico V et al. (2007) Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters (Review). The Cochrane Collaboration. The Cochrane Library, Issue 3
Anderson FA Jr, Wheeler HB, Goldberg RJ et al. (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Archives of internal medicine 151(5): 933–8
Bendz B, Rostrup M, Sevre K et al. (2000) Association between acute hypobaric hypoxia and activation of coagulation in human beings. Lancet 356(9242): 1657–8
Bern M, Lokich JJ, Wallach SR et al. (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Annals of internal medicine 112(6): 423–8
Couban S, Goodyear M, Burnell M et al. (2005) Randomized placebocontrolled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23(18): 4063–9
Dimberg LA, Mundt KA, Sulsky SI et al. (2001) Deep venous thrombosis associated with corporate air travel. J Travel Med 8(3): 127–32
Fraisse F, Holzapfel L, Couland JM et al. (2000) Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. American J respirator crit care med 161(4 Pt 1): 1109–14
Haas S (2004) Thromboembolieprophylaxe in der Chirurgie. Der Unfallchirurg 107(11): 1065–86
Heit JA, Silverstein MD, Mohr DN et al. (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based casecontrol study. Archives of internal medicine 160(6): 809–15
Hughes RJ, Hopkins RJ, Hill S et al. (2003) Frequency of venous thromboembolism in low to moderate risk long distance air travellers: the New Zealand Air Traveller’s Thrombosis (NZATT) study. Lancet 362(9401): 2039–44
Imberti D, Agnelli G, Ageno W et al. (2008) Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica 93(2): 273–8
Karthaus M, Kretzschmar A, Kroning H et al. (2006) Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebocontrolled phase III trial. Ann Oncol 17(2): 289–96
Kemkes-Matthes (2005) Prophylaxe bei Tumorpatienten. In: Haas S (Hrsg) Prävention von Thrombosen und Embolien in der Inneren Medizin. Heidelberg: Springer, S 162
Khorana AA (2007) The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patients. The oncologist 12(11): 1361–70
Kraaijenhagen RA, Haverkamp D, Koopman mm et al. (2000) Travel and risk of venous thrombosis. Lancet 356(9240): 1492–3
Landgraf H, Vanselow B, Schulte-Huermann D et al. (1994) Economy class syndrome: rheology, fluid balance, and lower leg edema during a simulated 12-hour long distance flight. Aviation, space, and environmental medicine 65(10 Pt 1): 930–5
Laporte S, Mismetti P, Decousus H et al. (2008) Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) registry. Circulation 117(13): 1711–6
Lapostolle F, Surget V, Borron SW et al. (2001) Severe pulmonary embolism associated with air travel. New England J Med 345(11): 779–83
Lassen MR, Borris LC, Nakov RL (2002) Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. New England J Med 347(10): 726–30
Monreal M, Lafoz E, Olive A et al. (1994) Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thrombosis and haemostasis 71(1): 7–11
Nicolaides AN, Arcelus J, Belcaro G et al. (1992) Prevention of venous thromboembolism. European Consensus Statement, 1–5 November 1991, developed at Oakley Court Hotel, Windsor (UK). Int Angiol 11(3): 151–9
Samama MM, Cohen AT, Darmon JY et al. (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. New England J Med 341(11): 793–800
Schobersberger W, Mittermayr M, Innerhofer P et al. (2004) Coagulation changes and edema formation during long-distance bus travel. Blood Coagul Fibrinolysis 15(5): 419–25
Schwarz T, Siegert G, Oettler W et al. (2003) Venous thrombosis after long-haul flights. Archives of internal med 163(22): 2759–64
Stricker H, Colucci G, Godio M et al. (2003) The influence of a prolonged sitting position on the biochemical markers of coagulation activation in healthy subjects: evidence of reduced thrombin generation. J Thromb Haemost 1(2): 380–1
Toff WD, Jones CI, Ford I et al. (2006) Effect of hypobaric hypoxia, simulating conditions during long-haul air travel, on coagulation, fibrinolysis, platelet function, and endothelial activation. Jama 295(19): 2251–61
Verso M, Agnelli G, Bertoglio S et al. (2005) Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23(18): 4057–62
Wessler S, Reiner L, Freiman DG et al. (1959) Serum-induced thrombosis. Studies of its induction, and evolution under controlled conditions in vivo. Circulation 20: 864–74
Literatur
Amarigiri SV, Lees TA (2000) Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 1: CD001484
Andrews EJ Jr, Fleischner AC (2005) Sonography for deep venous thrombosis: current and future applications. Ultrasound Q 21: 213–225
Boccalon H, Elias A, Chalé JJ et al. (2000) Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrennes study. Arch Intern Med 160: 1769–1773
Borly L, Wille-Jorgensen P, Rasmussen MS (2005) Systematic review of thromboprophylaxis in colorectal surgery-an update. Colorectal Dis 7: 122–127
Brandjes DP, Büller HR, Heijboer H et al. (1997) Randomised trial of the effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 349: 759–762
Cade JF (1982) High risk of the critically ill for venous thromboembolism. Crit Care Med 10: 448–450
Cham MD, Yankelevitz DF, Shaham D et al. (2000) Deep venous thrombosis: detection by using indirect CT venography. The Pulmonary angiography-indirect CT venography cooperative group. Radiology 216: 744–751
Cohen AT, Davidson BL, Gallus AS et al. (2006) Efficacy and saftey of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br Med J 332: 325–329
Crane C (1951) The use of heparin-gelatin-dextrose in venous thrombosis and pulmonary embolism. N Engl J Med 245: 926–929
Extended low-intensity anticoagulation for thrombo-embolism investigators (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349: 631–639
Geerts W, Ray JG, Colwell CW, Bergqvist D, Pineo GF, Lassen MR, Heit JA (2005) Prevention of venous thromboembolism. Chest 128: 3775–6
Geerts WH, Pineo GF, Heit JA et al. (2004) Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126: 338S–400S
Gould MK, Dembitzer AD, Sanders GD et al. (1999) Low-molecularweight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 130: 789–799
Hann CL, Streiff MB (2005) The role of vena caval filters in the management of venous thromboembolism. Blood Rev 19: 179–202
Hansson PO, Sörbo J, Eriksson H (2000) Recurrent venous thromboembolism after deep vein thrombosis: incidence, and risk factors. Arch Intern Med 160: 769–774
Heit JA (2005) Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 3: 1611–1617
Heit JA, Mohr DN, Silverstein MD et al. (2000) Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 160: 761–768
Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd (1999) Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 159: 445–53
Kapoor M, Kupfer YY, Tessler S (1999) Subcutaneous heparin prophylaxis significantly reduces the incidence of venous thromboembolic events in the critically ill (abstract). Crit Care Med 27(suppl.): A69
Kearon C, Ginsberg JS, Kovacs MJ et al. (2003) Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349: 631–639
Kearon C, Julian JA, Newman TE et al. (1998) Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 128: 663–677
Leizorovicz A, Cohen AT, Turpie AG et al. (2004) Randomized, placebocontrolled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110: 874–879
Leitlinien der deutschen Gesellschaft für Phlebologie. Diagnostik und Therapie der tiefen Bein-und Beckenvenenthrombose. AWMF online. www.uni-duesseldorf.de/WWW/AWMF/11/037-002.htm
Linkins L, Choi PT, Douketis JD (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 139: 893–900
Locker T, Goodacre S, Sampson F et al. (2006) Metaanalysis of plethysmography and rheography in the diagnosis of deep vein thrombosis. Emerg Med J 23: 630–635
Michiels JJ, Gadisseur A, van der Planken M et al. (2006) Different accuracies of rapid enzyme-linked immunosorbent, turbidimetric, and agglutination d-dimer assays for thrombosis exclusion: impact on diagnostic work-up of outpatients with suspected deep vein thrombosis and pulmonary embolism. Seminars in thrombosis and haemostasis 32: 678–693
Orbell JH, Smith A, Burnand KG et al. (2008) Imaging of deep vein thrombosis. Brit J Surg 95: 137–146
Palareti G, Cosmi B, Legnani C et al.; PROLONG Investigators (2006) Ddimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 355:1780–9
Palareti G, Legnani C, Cosmi B, Valdré L, Lunghi B, Bernardi F, Coccheri S (2003) Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 108:313–8
Pini M, Spyropoulos AC (2006) Prevention of venous thromboembolism. Seminars in thrombosis and hemostasis 32: 755–766
Prandoni P, Lensing AW, Prins MH et al. (2004) Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 141: 249–256
Prevent investigators (2003) Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348: 1425–1434
Qaseem A, Snow V, Barry P et al. (2007) Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 146(6): 454–8
Razavi MK, Wong H, Kee ST et al. (2002) Initial clinical results of tenecteplase (TNK) in catheter-directed thrombolytic therapy. J Endovasc Ther 9: 593–598
Rodger MA, Gagné-Rodger C, Howley HE et al. (2003) The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy. Thromb Res 112: 13–18
Samama MM, Cohen AT, Darmon JY et al. (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 341: 793–800
Snow V, Qaseem A, Barry P et al. (2007) Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 146: 204–210
Sugimoto K, Hofmann LV, Razavi MK et al. (2003) The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions. J Vasc Surg 37: 512–517
Turpie AG, Hirsh J, Gent M et al. (1989) Prevention of deep vein thrombosis in potential neurosurgical patients: a randomised trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. Arch Intern Med 149: 679–681
Wells PS et al. (1997) Value of assessment of pretest probability of deepvein thrombosis in clinical management. Lancet 350: 1795 (DI)
Wells PS, Hirsh J, Anderson DR et al. (1995) Accuracy of clinical assessment of deep-vein thrombosis. Lancet 345: 1326–1330
White RH, Zhou H, Kim J et al. (2000) A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. Arch Intern Med 160: 2033–2041
Literatur
Bayraktar Y, Harmanci O (2006) Etiology and consequences of thrombosis in abdominal vessels. World J Gastroenterol 12: 1165–1174
Biousse V, Tong F, Newman NJ (2003) Cerebral venous thrombosis. Curr Treatm Options Cardiovasc Med 5: 181–192
Brandao LR, Williams S, Kahr WHA, Ryan C, Temple M, Chan AKC (2006) Exercise-induced deep vein thrombosis of the upper extremity. 1. Literature review. Acta Haematol 115: 214–220
Brandt LJ, Boley SJ (2000) AGA technical review on intestinal ischemia. American Gastrointestinal Association. Gastroenterology 118: 954–968
Canhão P, Cortesão A, Cabral M, Ferro JM, Stam J, Bousser MG, Barinagarrementeria F, for the ISCVT Investigators (2008) Are steroids useful to treat cerebral venous thrombosis? Stroke 39: 105–110
Canhão P, Falcão F, Ferro JM (2003) Thrombolytics for cerebral sinus thrombosis. A systematic review. Cerebrovasc Dis 15: 159–166
Denninger MH, Chait Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Erlinger S, Briere J, Valla D (2000) Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 31: 587–591
Dentali F, Crowther M, Ageno W (2006) Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a metaanalysis. Blood 107: 2766–2773
De Bruijn SFTM, Stam J, for the Cerebral Venous Sinus Thrombosis Study Group (1999) Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke 30: 484–488
De Bruijn SFTM, Stam J, Kapelle LJ, for the CVST Study Group (1996) Thunderclap headache as first symptom of cerebral venous sinus thrombosis. Lancet 348: 1623–1625
DeVeber G, Andrew M, Adams C et al. (2001) for the Canadian Pediatric Ischemic Stroke Study Group () Cerebral sinovenous thrombosis in children. N Engl J Med 345: 417–423
Eckstein HH (2003) Die akute mesenteriale Ischämie. Chirurg 74: 419–431
Einhäupl KM, Villringer A, Meister W, Mehraein S, Garner C, Pellkofer M, Haberl RL, Pfister HW, Schmiedek P (1991) Heparin treatment in sinus venous thrombosis. Lancet 338: 597–600
Kalbag RM, Woolf AL (1967) Cerebral Venous Thrombosis. With Special Reference to Primary Aseptic Thrombosis. London: Oxford University Press, p 1–280
Kastenbauer S, Pfister HW (2003) Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain, 126: 1015–1025
Kosinski CM, Mull M, Schwarz M, Koch B, Biniek R, Schläfer J, Milkereit E, Willmes K, Schiefer J (2004) Do normal D-dimer levels exclude cerebral sinus thrombosis? Stroke 35: 2820–2825
Kuehnen J, Schwartz A, Neff W, Hennerici M (1998) Cranial nerve syndrome in thrombosis of the transverse/sigmoid sinuses. Brain 121: 381–388
Lock G, Schölmerich J (2004) Akute mesenteriale Durchblutungsstörungen. Intensivmed 41: 153–162
Nowak-Göttl U, Junker R, Hatmeier M, Koch HG, Münchow M, Assmann G, von Eckardstein A (1999) Increased lipoprotein (a) is an important risk factor for venous thrombembolism in childhood. Circulation 100: 743–748
Renowden S (2004) Cerebral venous sinus thrombosis. Eur Radiol 14: 215–226
Stolz E, Valdueza JM, Grebe M et al. (2007) Anemia as a risk factor for cerebral venous thrombosis? An old hypothesis revisited. Results of a prospective study. J Neurol 254(6): 729–34
Stolz E, Rahimi A, Gerriets T, Kraus J, Kaps M (2005) Cerebral venous thrombosis: an all or nothing disease? Prognostic factors and longterm outcome. Clin Neurol Neurosurg 107: 99–107
Literatur
Agnelli G (2004) Prevention of venous thromboembolism in surgical patients. Circulation 110: IV4–12
Agnelli G, Prandoni P, Becattini C et al. (2003) Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 139: 19–25
Bates SM, Greer IA, Hirsh J, Ginsberg JS (2004) Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 627S–44S
Becattini C, Vedovati MC, Agnelli G (2007) Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 116: 427–33
Bergqvist D, Agnelli G, Cohen AT et al. (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346: 975–80
Binder L, Pieske B, Olschewski M et al. (2005) N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 112: 1573–9
Buller HR, Davidson BL, Decousus H et al. (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349: 1695–702
Cohen AT, Davidson BL, Gallus AS et al. (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332: 325–9
Diener HC, Ringelstein EB, von Kummer R et al. (2006) Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. Stroke 37: 139–44
Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P (2007) The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 147: 766–74
Encke A, Haas S, Krauspe R et al. (2003) Stationäre und ambulante Thromboembolieprophylaxe in der Chirurgie und der perioperativen Medizin: Interdisziplinäre Leitlinie. Phlebologie 32: 164–9
Geerts WH, Pineo GF, Heit JA et al. (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 338S–400S
Hansson PO, Sorbo J, Eriksson H (2000) Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 160: 769–74
Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton LJ (2000) Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 160: 761–8
Interdisziplinäre S2-Leitlinie (2005) Diagnostik und Therapie der Bein-und Beckenvenenthrombose und der Lungenembolie. Vasa 34: 15–24
Iorio A, Guercini F, Pini M (2003) Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 1: 1906–13
Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 454S–545S
Konstantinides S (2008) Clinical practice. Acute pulmonary embolism. N Engl J Med 359: 2804–2813
Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W (2002) Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 347: 1143–50
Konstantinides S, Geibel A, Kasper W, Olschewski M, Blumel L, Just H (1998) Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism [see comments]. Circulation 97: 1946–51
Kucher N, Rossi E, De Rosa M, Goldhaber SZ (2005) Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med 165: 1777–81
Le Gal G, Righini M, Roy PM, Sanchez O, Aujesky D, Bounameaux H, Perrier A (2006) Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 144: 165–171
Leacche M, Unic D, Goldhaber SZ et al. (2005) Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg 129: 1018–23
Lee AY, Levine MN, Baker RI et al. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349: 146–53
Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ (2004a) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110: 874–9
Leizorovicz A, Mismetti P (2004b) Preventing venous thromboembolism in medical patients. Circulation 110: IV13–IV19
Linkins LA, Choi PT, Douketis JD (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 139: 893–900
Palareti G, Cosmi B, Legnani C et al. (2006) D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355: 1780–9
Perrier A (2007) Contemporary diagnostic algorithm for the hemodynamically stable patient with suspected pulmonary embolism. In: Konstantinides SV, editor. Management of acute pulmonary embolism. Totowa: Humana Press, p 91–103
Perrier A, Roy PM, Sanchez O et al. (2005) Multidetector-row computed tomography in suspected pulmonary embolism. N Engl J Med 352: 1760–8
Prandoni P, Lensing AW, Cogo A et al. (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125: 1–7
Puls M, Dellas C, Lankeit M et al. (2007) Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. Eur Heart J 28: 224–9
Quinlan DJ, McQuillan A, Eikelboom JW (2004) Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 140: 175–83
Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S (1993) The weight-based heparin dosing nomogram compared with a “standard Care„ nomogram. A randomized controlled trial. Ann Intern Med 119: 874–81
Samama MM, Cohen AT, Darmon JY et al. (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341: 793–800
Scridon T, Scridon C, Skali H, Alvarez A, Goldhaber SZ, Solomon SD (2005) Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism. Am J Cardiol 96: 303–5
Stein PD, Woodard PK, Weg JG et al. (2007) Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II Investigators. Radiology 242: 15–21
Stein PD, Fowler SE, Goodman LR et al. (2006) Multidetector computed tomography for acute pulmonary embolism. N Engl J Med 354: 2317–27
Torbicki A, Perrier A, Konstantinides SV et al. (2008) Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 29: 2276–2315
Torbicki A, Galie N, Covezzoli A, Rossi E, De Rosa M, Goldhaber SZ (2003) Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol 41: 2245–51
van Belle A, Buller HR, Huisman MV et al. (2006) Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 295: 172–9
Wan S, Quinlan DJ, Agnelli G, Eikelboom JW (2004) Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 110: 744–9
Wells PS, Anderson DR, Rodger M et al. (2001) Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med 135: 98–107
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Kyrle, P.A. et al. (2010). Venöse Thromboembolien. In: Pötzsch, B., Madlener, K. (eds) Hämostaseologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01544-1_32
Download citation
DOI: https://doi.org/10.1007/978-3-642-01544-1_32
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-01543-4
Online ISBN: 978-3-642-01544-1
eBook Packages: Medicine (German Language)